InvestorsHub Logo
Followers 18
Posts 1135
Boards Moderated 0
Alias Born 11/21/2017

Re: flipper44 post# 233353

Saturday, 06/15/2019 8:37:27 AM

Saturday, June 15, 2019 8:37:27 AM

Post# of 704420
That makes the most sense. Tumor heterogeneity is one of the big issues with GBM. New tumor has new antigens, thus it needs new DCVAX formula from the recurred lysate.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News